pING-HER3 Vaccine for Cancer - Clinical Trial
Email to Participate
felecia.walton@duke.edu
What is the Purpose of this Study?
Treatment
We are doing this study to find out how an experimental vaccine (pING-hHER3FL) works in your body and against your cancer.
What is the Condition Being Studied?
Objective
Cancer
Who Can Participate in the Study?
Key Eligibility
People who:
- Have the one of the following cancers:
--Breast
--Colon
--Lung
--Prostate
--Ovarian
--Cervical
--Endometrial
--Gastric (stomach)
--Pancreatic
--Bladder
--Head and neck
--Liver
--Esophageal
- Have been treated with surgery and/or chemotherapy and radiation
For more information about who can join this study, please contact the study team at felecia.walton@duke.edu.
Age Group
Adults
What is Involved?
Description
If you choose to do this study, you will:
- Get the study vaccine three times over 8 weeks
- Have occasional blood draws for 5 years
- Have a biopsy to collect tumor tissue, if necessary
Study Details
Full Title
ASSESSING THE IMMUNOGENICITY OF pING-hHER3FL VACCINE IN PATIENTS WITH RESECTED MALIGNANCIES
Principal Investigator
Medical Oncologist
Protocol Number
IRB:
PRO00104093
NCT:
NCT03832855
Phase
Phase
I
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Email felecia.walton@duke.edu